Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GRAY Graybug Vision	$2.79 +1.5%	$2.43	$5.00 ▼ $22.12	$4.38M	1.2	2,165 shs	92,466 shs
IBIO iBio	$0.79 +1.9%	$0.73	$0.56 ▼ $6.89	$15.26M	0.6	1.39 million shs	411,981 shs
MTNB Matinas Biopharma	$2.13 +22.4%	$1.10	$0.47 ▼ $5.24	$10.84M	1.32	448,793 shs	358,565 shs
TAOX Synaptogenix	$7.65 +18.6%	$0.00	$1.84 ▼ $11.98	$22.49M	1.87	279,270 shs	337,606 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GRAY Graybug Vision	+1.45%	+17.97%	-20.06%	+55.00%	-28.46%
IBIO iBio	+1.89%	+6.72%	+3.98%	-3.30%	-61.03%
MTNB Matinas Biopharma	+22.41%	-9.75%	+123.27%	+162.32%	+1,047.01%
TAOX Synaptogenix	+18.60%	-8.93%	+764,999,900.00%	+764,999,900.00%	+764,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GRAY Graybug Vision	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IBIO iBio	1.9179 of 5 stars	3.5	0.0	0.0	0.0	2.5	0.0	0.6
MTNB Matinas Biopharma	0.7235 of 5 stars	0.0	5.0	0.0	0.0	1.1	0.0	0.6
TAOX Synaptogenix	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GRAY Graybug Vision	0.00	N/A	N/A	N/A
IBIO iBio	3.00	Buy	$5.00	532.11% Upside
MTNB Matinas Biopharma	2.00	Hold	N/A	N/A
TAOX Synaptogenix	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest GRAY, IBIO, TAOX, and MTNB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/25/2025	IBIO iBio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GRAY Graybug Vision	N/A	N/A	N/A	N/A	$1.67 per share	N/A
IBIO iBio	$375K	41.46	N/A	N/A	$1.41 per share	0.56
MTNB Matinas Biopharma	N/A	N/A	N/A	N/A	$4.43 per share	N/A
TAOX Synaptogenix	N/A	N/A	N/A	N/A	$4.95 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GRAY Graybug Vision	-$35.60M	-$24.23	N/A	N/A	N/A	N/A	-77.61%	-71.34%	N/A
IBIO iBio	-$24.91M	N/A	0.00	N/A	N/A	N/A	-73.15%	-45.51%	N/A
MTNB Matinas Biopharma	-$22.94M	-$3.89	N/A	∞	N/A	N/A	-123.06%	-94.28%	N/A
TAOX Synaptogenix	-$12.77M	-$20.16	N/A	∞	N/A	N/A	-277.76%	-150.79%	N/A

Latest GRAY, IBIO, TAOX, and MTNB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/15/2025	Q2 2025	TAOX Synaptogenix	N/A	-$11.26	N/A	-$11.26	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GRAY Graybug Vision	N/A	N/A	N/A	N/A	N/A
IBIO iBio	N/A	N/A	N/A	N/A	N/A
MTNB Matinas Biopharma	N/A	N/A	N/A	N/A	N/A
TAOX Synaptogenix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GRAY Graybug Vision	N/A	10.73	10.72
IBIO iBio	0.05	1.76	1.76
MTNB Matinas Biopharma	N/A	5.53	5.53
TAOX Synaptogenix	N/A	20.52	72.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GRAY Graybug Vision	49.94%
IBIO iBio	7.90%
MTNB Matinas Biopharma	11.77%
TAOX Synaptogenix	10.34%

Insider Ownership

Company	Insider Ownership
GRAY Graybug Vision	7.94%
IBIO iBio	0.58%
MTNB Matinas Biopharma	4.60%
TAOX Synaptogenix	2.73%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GRAY Graybug Vision	27	1.57 million	20.25 million	Not Optionable
IBIO iBio	100	19.66 million	9.82 million	N/A
MTNB Matinas Biopharma	30	5.09 million	4.60 million	N/A
TAOX Synaptogenix	4	3.49 million	1.35 million	N/A

GRAY, IBIO, TAOX, and MTNB Headlines

Recent News About These Companies

Wall Street Zen Downgrades Synaptogenix (NASDAQ:TAOX) to Sell

August 19, 2025 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRAY, IBIO, TAOX, and MTNB Company Descriptions

Graybug Vision NASDAQ:GRAY

$2.79 +0.04 (+1.45%)

As of 08/21/2025

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.

iBio NYSE:IBIO

$0.79 +0.01 (+1.89%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.78 -0.01 (-1.01%)

As of 08/22/2025 07:50 PM Eastern

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

Matinas Biopharma NYSE:MTNB

$2.13 +0.39 (+22.41%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.10 -0.03 (-1.36%)

As of 08/22/2025 07:55 PM Eastern

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

Synaptogenix NASDAQ:TAOX

$7.65 +1.20 (+18.60%)

As of 08/22/2025 04:00 PM Eastern

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time